A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Trial Profile

A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Nivolumab (Primary) ; Capecitabine; Irinotecan; Temsirolimus
  • Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms NivoPlus
  • Most Recent Events

    • 23 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 23 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top